EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

FDA-Approved Drug Repurposing as p53 Mutants Rescue Candidates Using Structure-Based Virtual Screening and Molecular Simulations

Mena Abdelsayed, Yassir Boulaamane iD

International Journal of Molecular Sciences · 27.07.2026 · 27 (15) · 6677

DOI: 10.3390/ijms27156677 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 27.07.2026. Verfasst von Mena Abdelsayed und 1 weiteren Autor:innen. Beteiligte Einrichtung: Lankenau Institute for Medical Research, Philadelphia, PA 19096, USA. Hauptthemen laut MEDLINE: Tumor Suppressor Protein p53, Drug Repositioning, Mutation. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The restoration of mutant p53 stability is a highly sought-after strategy in targeted cancer therapy. This study presents a structure-based virtual screening and molecular dynamics approach to nominate FDA-approved drugs as candidate stabilizers of mutant p53 for downstream experimental validation. A virtual screening library of FDA-approved compounds was docked against three representative p53 mutants (7DHY, 7DHZ, and 7V97) to evaluate their binding potential. The prioritized candidates demonstrated consistent, multi-conformer binding affinities. Protein–ligand interaction profiling revealed that the candidate DB09280 possesses a highly dense interaction network, particularly against the V272M and R249S variants. Residue-level analysis of the G245S structural mutant showed that DB09280 uniquely engages His19, a crucial residue for zinc coordination, and forms stabilizing contacts with adjacent flexible loop residues, including ASN35 and PRO32. Subsequent 500 ns molecular dynamics simulations were consistent with DB09280 acting as a putative conformational clamp on the timescale sampled. The ligand-bound (holo) system exhibited substantially reduced global structural drift (RMSD) and attenuated local residue fluctuation (RMSF) within the core domain compared to the highly unstable apo state. Principal component analysis further indicated that DB09280 restricts the broad conformational sampling of the mutant into a stable, dominant basin within the sampled trajectory. Together, these computational findings nominate DB09280 as a promising candidate structural stabilizer of mutant p53 worthy of experimental follow-up. We emphasize that the in silico stabilization observed here is not equivalent to functional rescue of p53 transcriptional activity; biochemical, biophysical, and cell-based assays will be required to establish whether DB09280 restores wild-type-like DNA binding or tumor-suppressor function in mutant p53 contexts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor Suppressor Protein p53Drug RepositioningMutationMolecular Dynamics SimulationHumansLigandsProtein BindingMolecular Docking SimulationUnited StatesUnited States Food and Drug AdministrationDrug Approval

Stichwörter der Autor:innen

allosteric modulationdrug repurposingmolecular dynamics simulationsp53 mutantstructural stabilizationvirtual screening

Substanzen

Tumor Suppressor Protein p53Ligands

Autor:innen und Institutionen

  • Lankenau Institute for Medical Research, Philadelphia, PA 19096, USA.
  • Laboratory of Innovative Technologies, National School of Applied Sciences of Tangier, Abdelmalek Essaadi University, Tetouan 93000, Morocco.

ORCID-Profile: Yassir Boulaamane

Zitieren

APA

Abdelsayed, M., & Boulaamane, Y. (2026). FDA-Approved Drug Repurposing as p53 Mutants Rescue Candidates Using Structure-Based Virtual Screening and Molecular Simulations. International Journal of Molecular Sciences, 27(15), 6677. https://doi.org/10.3390/ijms27156677

Vancouver

Abdelsayed M, Boulaamane Y. FDA-Approved Drug Repurposing as p53 Mutants Rescue Candidates Using Structure-Based Virtual Screening and Molecular Simulations. International Journal of Molecular Sciences. 2026;27(15):6677. doi:10.3390/ijms27156677

BibTeX
@article{Abdelsayed2026,
  author = {Abdelsayed, Mena and Boulaamane, Yassir},
  title = {FDA-Approved Drug Repurposing as p53 Mutants Rescue Candidates Using Structure-Based Virtual Screening and Molecular Simulations},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {15},
  pages = {6677},
  doi = {10.3390/ijms27156677}
}
Kostenlos starten →